EBS News and Press, Emergent Biosolutions Inc. From 11/08/22

Emergent Biosolutions press release ( NYSE: EBS ): Q3 Non-GAAP EPS of -$1.27 misses by $1.14 . Revenue of $240M (-27.1% Y/Y) misses by $26.35M . Guidance 2022: Total Revenues $1.05B to $1.1B. Prior total revenue outlook of $1.15B to $1.25B vs. con...

GAITHERSBURG, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2022. “For more than 20 years, Emergent has been a dependable partner to customers, including the U.S. and...

GAITHERSBURG, Md., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company’s adjuvanted single dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in pr...

SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies ...

GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2022, recent business developments, and financial outlook f...

GAITHERSBURG, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA ® (brincidofovir), the first oral antiviral approved by the U.S. Food and Drug Administration ...

The White House announced new measures to fight the U.S. opioid epidemic on Friday, including nearly $1.5B in funding allocated to states and territories to raise awareness and increase access to overdose reversal agents such as naloxone. According to the U.S. Centers for Disease Co...

Emergent BioSolutions Inc. ( NYSE: EBS ), a company known for its contract manufacturing work, announced Tuesday the dosing of the first participant in its Phase 1 trial for EBS-LASV, an experimental vaccine for Lassa virus infection. EBS shares gained ~9% in pre-market tr...

GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being deve...

Biden administration health officials will testify before the Senate Health, Education, Labor and Pensions Committee at a hearing in mid-September, Bloomberg reported. On August 23, Sen. Patty Murray (D-Wash.), chairwoman of the committee, sent a letter to Dawn O'Conne...